Vertex Pharmaceuticals Inc

Healthcare · Biotechnology

522.40$ +1.2% vs. previous close Closing price · As of: Sep 24, 2026

Statements

Income Statement

Vertex Pharmaceuticals Inc (VRTX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 3,334 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size % Per share

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement VRTX
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26	LTM
Revenue	414	459	715	544	578	652	641	752	785	870	858	941	950	1,413	1,515	1,524	1,538	1,628	1,724	1,793	1,984	2,073	2,098	2,196	2,334	2,303	2,375	2,493	2,484	2,518	2,687	2,646	2,772	2,912	2,770	2,965	3,076	3,227	2,987	3,334	12,624
Cost of Revenue	54	60	47	71	73	84	72	104	111	122	95	136	132	185	162	185	186	203	192	228	237	247	246	262	289	283	267	309	319	368	343	372	393	423	363	408	415	466	393	489	1,763
Gross Profit	360	398	668	473	505	568	569	648	673	748	763	806	818	1,228	1,353	1,340	1,352	1,425	1,532	1,565	1,748	1,825	1,852	1,934	2,045	2,019	2,108	2,185	2,165	2,150	2,345	2,274	2,379	2,489	2,407	2,557	2,662	2,761	2,594	2,845	10,862
Research & Development	275	248	274	289	455	307	311	338	331	438	339	379	556	480	449	421	493	467	456	1,407	494	694	603	600	645	694	743	896	862	1,352	866	5,416	876	999	980	978	1,032	974	962	994	3,961
Selling, General & Administrative	106	110	113	127	121	135	130	137	137	153	147	157	160	195	182	192	185	212	192	195	199	255	208	166	244	269	239	262	264	369	343	372	372	378	396	425	445	487	494	582	2,008
Total Operating Expenses	381	358	387	417	576	441	440	475	468	591	487	536	716	675	631	622	678	678	648	1,603	692	950	811	828	918	986	1,329	1,159	1,126	1,161	1,209	5,788	1,263	1,463	1,777	1,406	1,475	1,461	1,456	1,598	5,990
Operating Income	-22	40	271	53	-326	126	129	173	206	128	277	270	99	551	720	718	672	746	888	-38	1,055	878	1,041	1,106	1,127	1,034	779	1,026	1,038	989	1,140	-3,515	1,116	1,026	630	1,151	1,186	1,300	1,138	1,247	4,872
Interest Expense	20	20	17	15	14	13	17	18	8.1	4.8	15	15	15	14	14	14	14	16	16	15	15	15	15	15	14	12	11	11	11	11	10	9.9	7.5	2.8	3.0	3.7	3.3	3.3	–	–	–
Pre-Tax Income	-42	20	254	36	-417	112	215	217	137	32	320	327	71	677	658	825	746	889	821	-44	1,083	871	955	1,024	1,176	1,077	892	1,162	1,179	1,148	1,279	-3,391	1,224	1,137	730	1,283	1,299	1,331	1,253	1,392	5,275
Income Tax Expense	0.5	-7.5	4.0	4.3	-126	10	-13	10	8.1	-1,493	52	60	13	94	55	-13	78	284	168	-111	231	101	193	214	246	258	192	246	144	179	180	202	179	224	84	250	216	140	222	292	869
Net Income	-42	33	248	18	-103	101	210	207	129	1,551	269	267	58	583	603	837	667	604	653	67	852	770	762	811	931	819	700	916	1,035	969	1,100	-3,594	1,045	913	646	1,033	1,083	1,191	1,031	1,100	4,405
EBITDA	-4.3	56	285	65	-388	141	242	245	164	56	362	370	111	717	698	865	786	934	865	2.6	1,130	920	1,006	1,076	1,227	1,127	942	1,214	1,232	1,217	1,343	-3,327	1,285	1,184	782	1,338	1,356	1,387	1,309	1,392	5,445

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Income Statement

Cookie settings